Abstracts tagged "Vasculitis"

Abstract Number: 2227 • ACR Convergence 2022
Active Takayasu Arteritis Is Associated with Plasma and Cellular Measures of Endothelial Dysfunction
Marta Peverelli¹, Andrew Porter¹, Kerri Malone², Allan Kiprianos¹, Tom McKinnon¹, Charis Pericleous¹, Robert Maughan¹ and Justin Mason¹, ¹Imperial College London, London, United Kingdom, ²European BioInformatics Institute, Hinxton, United Kingdom
Background/Purpose: The accurate assessment of disease activity and progression is a major challenge in Takayasu Arteritis (TA). An improved understanding of disease pathogenesis is required…
Abstract Number: 0456 • ACR Convergence 2022
Application of Adult ACR/EULAR 2022 Classification Criteria in Pediatric Vasculitis Patients
Else Bosman¹, Kimberly Morishita² and David Cabral³, ¹University of British Columbia, Vancouver, BC, Canada, ²University of British Columbia - Vancouver, Vancouver, BC, Canada, ³BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Previous classification of childhood vasculitis used 1990 ACR criteria for classifying granulomatosis with polyangiitis (GPA) and eosinophilic granulomatosis with polyangiitis (EGPA),. In 2008, EULAR/PRINTO/PRES…
Abstract Number: 0482 • ACR Convergence 2022
Role of miR-146a and miR-146b in Giant Cell Arteritis
Martina Bonacini¹, Alessandro Rossi¹, Ilaria Ferrigno², Francesco Muratore¹, Luigi Boiardi¹, Alberto Cavazza¹, Luca Cimino², Angelo Ghidini¹, Giuseppe Malchiodi¹, Marc Corbera-Bellalta³, Maria C Cid³, Alessandro Zerbini¹, Carlo Salvarani⁴ and Stefania Croci¹, ¹Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy, ²Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, University of Modena and Reggio Emilia, Reggio Emilia, Italy, ³Hospital Clinic, University of Barcelona, Barcelona, Spain, ⁴Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Università di Modena e Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: Giant cell arteritis (GCA) is an inflammatory disease of large and medium-sized arteries. MiRNAs (miR) are small, non-coding RNAs that inhibit gene expression at…
Abstract Number: 0953 • ACR Convergence 2022
Increased Risk of Preterm Delivery Phenotypes and Hypertensive Disorders of Pregnancy in First Deliveries of Patients with Systemic Vasculitis
Audra Horomanski¹, Gary Shaw², Jonathan Mayo³ and Julia Simard⁴, ¹Stanford University, Stanford, CA, ²Stanford University School of Medicine, Palo Alto, ³Stanford University, Stanford, ⁴Stanford University School of Medicine, Palo Alto, CA
Background/Purpose: Systemic vasculitides are rare disorders characterized by vascular inflammation that can affect virtually every organ system. Recent treatment advances have increased life expectancy and…
Abstract Number: 1356 • ACR Convergence 2022
Patient-perceived Disease Burden and Self-reported Medication Adherence in Systemic Autoimmune Diseases: A Monocentric Observational Study
Camille Mettler¹, Veronique Le Guern², Paul Legendre¹, Caroline Morbieu¹, Tali-Anne Swebel¹, Xavier Puéchal³, Pascal Cohen³, Hicham Kardaoui¹, Alexandre Moores¹, Luc Mouthon³, Nathalie Costedoat-Chalumeau⁴ and Benjamin Terrier³, ¹Department of Internal Medicine, National Referral Center for Rare Systemic and Autoimmune Diseases, Cochin Hospital, Paris, France, ²Hôpital Cochin, Paris, France, ³National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ⁴Inserm DR Paris 5, Paris, France
Background/Purpose: Systemic autoimmune diseases (AID) are chronic conditions with significant burden related to the disease itself, its management, and treatments. Burden refers to the workload…
Abstract Number: 1572 • ACR Convergence 2022
CD40, BLK and BANK1 in the Pathogenesis of Immunoglobulin-A Vasculitis
Fernanda Genre¹, Sara Remuzgo-Martinez¹, Veronica Pulito-Cueto¹, JOAO CARLOS BATISTA LIZ², Diana Prieto-Peña¹, Belén Atienza-Mateo¹, Belén Sevilla-Pérez³, Javier Llorca⁴, Norberto Ortego⁵, María Teresa Leonardo⁶, Ana Peñalba⁶, F. Javier Narváez⁷, Luis Martín-Penagos⁸, Emilio Rodrigo⁸, Cristina Gomez-Fernandez⁹, Lara Belmar-Vega⁸, José A. Miranda-Filloy¹⁰, Luis Caminal-Montero¹¹, Paz Collado¹², Pedro Rodriguez-Jimenez¹³, Diego De Argila¹⁴, Patricia Quiroga-Colina¹⁵, Esther Vicente-Rabaneda¹⁶, Enrique Rubio¹⁷, Manuel León Luque¹⁷, Juan María Blanco-Madrigal¹⁸, Eva Galíndez-Agirregoikoa¹⁹, Javier Martín²⁰, Santos Castañeda¹⁶, Ricardo Blanco²¹, Miguel Ángel González-Gay²² and Raquel Lopez Mejias²³, ¹Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Ilerna, Madrid, Spain, ³Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, ⁴Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain, ⁵Medicine Department, Universidad de Granada, Granada, Spain, ⁶Division of Pediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁷Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁸Division of Nephrology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁹Division of Dermatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹⁰Division of Rheumatology, Hospital Universitario Lucus Augusti, Lugo, Spain, ¹¹Division of Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain, ¹²Division of Rheumatology, Hospital Universitario Severo Ochoa, Madrid, Spain, ¹³Dermatology Department, Hospital Universitario de La Princesa, Madrid, ¹⁴Dermatology Department, Hospital Universitario de La Princesa, Madrid, Spain, ¹⁵Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ¹⁶Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ¹⁷Division of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ¹⁸Division of Rheumatology, Hospital Universitario de Basurto, Bilbao, Spain, ¹⁹Basurto University Hospital, Bilbao, Spain, ²⁰Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, PTS Granada, Granada, Spain, ²¹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ²²Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ²³IDIVAL, Santander, Spain
Background/Purpose: CD40 is a membrane glycoprotein expressed on B cells surface that activates antigen presenting cells [1]. BLK and BANK1 are components of B cells…
Abstract Number: 2228 • ACR Convergence 2022
Development of the Takayasu’s Arteritis Integrated Disease Activity Index
Chiara Marvisi¹, Ertugrul Cagri Bolek², Mark Ahlman³, Hugh Alessi⁴, Christopher Redmond⁵, Peter Merkel⁶, Carlo Salvarani⁷, Kaitlin Quinn⁸ and Peter Grayson⁹, ¹Università di Modena e Reggio Emilia and National Institute of Arthritis & Musculoskeletal & Skin Diseases, National Institutes of Health, Bethesda, MD, ²Vasculitis Translational Research Program, NIAMS, NIH, US, Lanham MD, MD, ³National Institutes of Health, Clinical Center, Radiology and Imaging Sciences, Bethesda, MD, ⁴National Institutes of Health, Bethesda, MD, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Azienda USL -IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Reggio Emilia, Italy, ⁸National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ⁹National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: Disease activity indices that accurately assess inflammation in Takayasu's arteritis (TAK) are needed. While clinical assessment is often considered the gold standard, determining if…
Abstract Number: 0459 • ACR Convergence 2022
The Use of Intravenous Methylprednisolone in Patients with Giant Cell Arteritis: A Population-Based Study
Hampus Henningson¹, Björn Hammar², Carl Turesson³ and Aladdin Mohammad¹, ¹Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden, ²Ophthalmology, Department of Clinical Sciences, Lund University, Lund, Sweden, ³Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden
Background/Purpose: Giant cell arteritis (GCA) is the most common vasculitis in the age-group 50 years and older. Cranial involvement is common and can lead to…
Abstract Number: 0483 • ACR Convergence 2022
Giant Cell Arteritis: Physical Examination of the Superficial Temporal Arteries Can Predict Temporal Artery Biopsy Result
Giuseppe Germanò¹, Pierluigi macchioni², Giulia Klinowski¹, Alberto Cavazza³, Luigi Boiardi³ and Carlo Salvarani⁴, ¹Arcispedale IRCCS Santa Maria Nuova, Reggio Emilia, Emilia-Romagna, Italy, ²Arcispedale IRCCS Santa Maria Nuova, Reggio Emilia, Italy, ³Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁴Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Università di Modena e Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: The detection of temporal arterial abnormalities (TA) is one of the ACR 1990 criteria to define the diagnosis of cranial Giant Cell Arteritis (GCA).…
Abstract Number: 0979 • ACR Convergence 2022
Belimumab Effects on Skin in Patients with Systemic Lupus Erythematosus: A Pooled Post Hoc Analysis of Five Phase 3, Randomized, Placebo-Controlled Clinical Trials
Susan Manzi¹, Jorge Sanchez-Guerrero², Naoto Yokogawa³, Joerg Wenzel⁴, Josephine C. Ocran-Appiah⁵, Munther Khamashta⁶, Julia H N Harris⁷, Bernie Rubin⁸, Norma Lynn Fox⁹, Roger A Levy¹⁰ and Victoria Werth¹¹, ¹Allegheny Health Network, Lupus Center of Excellence, Wexford, PA, ²University of Toronto, Division of Rheumatology, Department of Medicine Mount Sinai Hospital/University Health Network, Toronto, ON, Canada, ³Tokyo Metropolitan Tama Medical Center, Department of Rheumatic Diseases, Tokyo, Japan, ⁴University Hospital of Bonn, Department of Dermatology and Allergy, Bonn, Germany, ⁵GlaxoSmithKline, Clinical Science Immunology, Rockville, MD, ⁶GlaxoSmithKline, Medical Affairs, Dubai, United Arab Emirates, ⁷GlaxoSmithKline, Immunology Biostatistics, Brentford, United Kingdom, ⁸GlaxoSmithKline, US Medical Affairs and Immuno-inflammation, Durham, NC, ⁹GlaxoSmithKline, Clinical Development *At time of study, Collegeville, PA, ¹⁰GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, ¹¹Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia
Background/Purpose: Mucocutaneous manifestations affect >80% of patients (pts) with SLE and can contribute to their poor quality of life through unwanted attention, self-consciousness, emotional symptoms,…
Abstract Number: 1549 • ACR Convergence 2022
Toward Safer Glucocorticoid Therapy
Xingyu Pan¹, Qiongqiong Hou¹, Jiahui Xu¹, Yake Ma¹, Jiawen Li¹, Min Li¹, Jing Su¹, Xuerou Shi¹, William Bracken² and David Katz², ¹WuXi AppTec, Nantong, China, ²Sparrow Pharmaceuticals, Portland, OR
Background/Purpose: SPI-62 is a potent 11b-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor entering Phase 2 development as adjunctive therapy to prednisolone in polymyalgia rheumatica, as well…
Abstract Number: 1573 • ACR Convergence 2022
Von – Willebrand Factor, a Possible Marker for Disease Activity in Vasculitis
Jomana mazareeb¹, shiri keret¹, Abid Awisat¹, Itzhak Rosner², Michel Rozenbaum³, Lisa Kaly¹, Gleb Slobodin¹ and Doron Rimar¹, ¹Bnai Zion Medical Center, Haifa, Israel, ²Bnai Zion Medical Center/Technion, Haifa, Israel, ³Bnei Zion Medical Center, Hertzeliya, Israel
Background/Purpose: Vasculitis is an inflammation of blood vessels. While in many cases markers of inflammation as c- reactive protein (CRP) or erythrocytes sedimentation rate (ESR)…
Abstract Number: 2229 • ACR Convergence 2022
Ultrasound Localization Microscopy as a New Tool for Takayasu’s Arteritis Activity Assessment, a Deep Insight Within Carotid Wall Inflammation
Guillaume Goudot¹, Anatole Jimenez², Nassim Mohamedi³, jonas Sitruk³, Lina Khider¹, Hélène Mortelette³, Clément Papadacci², Fabien Hyafil⁴, Mickaël Tanter², Emmanuel Messas¹, Mathieu Pernot² and Tristan Mirault¹, ¹Vascular medicine department, Georges Pompidou European hospital, APHP, Université Paris Cité, INSERM U970 PARCC, Paris, Ile-de-France, France, ²Physics for Medicine Paris, INSERM U1273, ESPCI Paris, CNRS FRE 2031, PSL Research University, Paris, France, ³Vascular medicine department, Georges Pompidou European hospital, APHP, Université Paris Cité, Paris, Ile-de-France, France, ⁴Nuclear medicine department, Georges Pompidou European hospital, APHP, Universite Paris Cite, INSERM U970 PARCC, Paris, Ile-de-France, France
Background/Purpose: Use of sulphur hexafluoride microbubbles (MB) with ultrasound allow to assess arterial wall vascularization through signal enhancement. The use of ultrafast imaging with MB…
Abstract Number: 0460 • ACR Convergence 2022
Baseline Glucocorticoid Toxicity in the Treatment of Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial
Naomi Patel¹, Xiaoqing Fu², yuqing zhang³ and John Stone⁴, ¹Massachusetts General Hospital, Sale Creek, TN, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Quincy, MA, ⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: Giant cell arteritis (GCA) requires treatment with high-dose, long-term glucocorticoids (GCs). The development of future GC toxicities may be predicted by baseline toxicities. Thus,…
Abstract Number: 0485 • ACR Convergence 2022
Assessing the Effectiveness of Tocilizumab in Newly Diagnosed Giant Cell Arteritis versus Refractory/recurrent Giant Cell Arteritis in Clinical Practice
Julio Sánchez-Martín¹, Javier Loricera², Clara Moriano³, Santos Castañeda⁴, F. Javier Narváez⁵, Vicente Aldasoro⁶, Olga Maiz⁷, Rafael Melero⁸, Juan Ignacio Villa Blanco⁹, Paloma Vela-Casasempere¹⁰, Susana Romero Yuste¹¹, José Luis Callejas¹², Eugenio De Miguel¹³, Eva Galíndez-Agirregoikoa¹⁴, Francisca Sivera¹⁵, Jesus Fernandez¹⁶, Carles Galisteo¹⁷, Ivan Ferraz Amaro¹⁸, Lara Sánchez-Bilbao¹, Monica Calderon-Goercke¹⁹, Miguel Ángel González-Gay²⁰ and Ricardo Blanco², ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Complejo Asistencial Universitario de León, León, Spain, ⁴Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁵Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Hospital Universitario de Navarra, Pamplona, Spain, ⁷Hospital Universitario de Donostia, San Sebastián, Spain, ⁸Complexo Hospitalario Universitario de Vigo, Vigo, Spain, ⁹Sierrallana Hospital, Torrelavega, Spain, ¹⁰Hospital General Universitario Alicante, Alicante, Spain, ¹¹Complexo Hospitalario Universitario, Pontevedra, Spain, ¹²Hospital San Cecilio, Granada, Spain, ¹³Hospital Universitario La Paz, Madrid, Spain, ¹⁴Basurto University Hospital, Bilbao, Spain, ¹⁵Hospital Universitario de Elda, San Vicente del Raspeig, Spain, ¹⁶Hospital de La Coruña, La Coruña, Spain, ¹⁷Hospital Parc Tauli,, Sabadel, Spain, ¹⁸Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ¹⁹Hospital de Sierrallana, Torrelavega, Spain, ²⁰Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Tocilizumab (TCZ) is the only biologic drug approved in giant cell arteritis (GCA), based in two clinical trials (CT) (1,2). CT included selected patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].